Adial Pharmaceuticals (US) announced the acquisition of Azora Therapeutics (US), a biopharmaceutical company, to bolster its pipeline with Azora's lead asset AT177. The deal includes an upfront private placement financing of up to $64 million in gross proceeds.
| Acquirer | Adial Pharmaceuticals (US) |
|---|---|
| Target | Azora Therapeutics (US) |
| Value | Undisclosed |
| Type | Acquisition |
| Closing Date | 2026-06-15 |
| Advisors (Buy-side) | Oppenheimer & Co. |
Adial Pharmaceuticals, a biopharmaceutical company focusing on the development of precision medicines for treating alcohol use disorder and cardiovascular diseases, has acquired Azora Therapeutics to enhance its pipeline with AT177, which is currently in preclinical development. The acquisition marks Adial's strategic move into additional therapeutic areas.
Deal Mechanics
The deal includes an upfront financing of up to $64 million in gross proceeds from a private placement. Additional funding may be available contingent upon the initiation of Azora’s Phase 1 clinical study for AT177, highlighting Adial's commitment to advancing this promising asset through early-stage development.
Strategic Rationale
The acquisition is aimed at expanding Adial Pharmaceuticals' portfolio by integrating a new and potentially transformative asset. Azora Therapeutics brings expertise in biopharmaceutical research and development, complementing Adial's existing capabilities. This move is expected to strengthen Adial’s position as a leader in the field of precision medicine.
Financial Context
Adial Pharmaceuticals’ decision to acquire Azora Therapeutics reflects its focus on strategic growth through targeted acquisitions. The deal will likely be funded from the private placement proceeds, allowing Adial to maintain financial discipline while expanding its pipeline and research capacity.
Outlook
The integration of Azora’s AT177 into Adial's portfolio is anticipated to bring significant value as it progresses through clinical development. This strategic move aligns with Adial's mission to deliver innovative precision medicine solutions for unmet medical needs.